Chardan analyst Keay Nakae downgraded Avidity Biosciences (RNA) to Neutral from Buy with a $72 price target after Novartis (NVS) announced an agreement to acquire Avidity for $72 per share in cash. The acquisition is expected to close in the first half of 2026, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences downgraded to Sector Perform from Outperform at RBC Capital
- Midday Fly By: Novartis to buy Avidity, Keurig Dr Pepper beats expectations
- Avidity Biosciences rises 42.5%
- Avidity Biosciences downgraded to Neutral from Buy at Citi
- Avidity Biosciences downgraded to Market Perform from Outperform at Leerink